Daiichi Sankyo Ltd ADR (OP:DSNKY)

21.39 +0.16 (+0.73%)

Streaming Delayed Price Updated: 2:44 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Daiichi Sankyo Ltd ADR

< Previous 1 2 3 Next >

AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer ↗

September 17, 2021

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu...

Via Benzinga

AstraZeneca, Daiichi Sankyo's Enhertu Shows Improved PFS Over Roche's Kadcyla In Breast Cancer ↗

August 09, 2021

AstraZeneca plc (NASDAQ: AZN) and Daiichi Sankyo Co Ltd (OTC: DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3...

Via Benzinga

Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu ↗

July 08, 2021

Daiichi Sankyo Co Ltd (OTC: DSKYF) and AstraZeneca plc (NASDAQ: AZN) have dosed the first patient in DESTINY-Gastric04, Phase 3 trial of Enhertu (...

Via Benzinga

Daiichi Sankyo To Stop Testing Inhaled Nafamostat In COVID-19 Patients In Japan ↗

June 15, 2021

Daiichi Sankyo Co Ltd (OTC: DSNKY) said it was halting the development of an existing drug for the treatment of COVID-19 without citing a reason. However, the...

Via Benzinga

Nipro To Provide Fill, Finish Services For AstraZeneca COVID-19 Shots In Japan: Reuters ↗

May 26, 2021

Japan's Nipro Corporation has signed an agreement to supply AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in Japan, reports Reuters. Nipro...

Via Benzinga

AstraZeneca, Daiichi Sankyo Partnered ADC Shows Promise In Hard-To-Treat Breast Cancer ↗

May 10, 2021

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OCTMKTS: DSNKY) have announced an update from their second antibody-drug conjugate (ADC) program...

Via Benzinga

LogicBio Therapeutics, CANbridge Ink Partnership For Development Of Gene Therapy Candidates ↗

April 27, 2021

CANbridge Pharmaceuticals Inc has entered into a strategic collaboration and licensing agreement with LogicBio Therapeutics Inc (NASDAQ: LOGC) to...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.